764714-59-2Relevant articles and documents
Synthesis of a bicyclic piperazine from l-aspartic acid and application of a fluoride-promoted SNAr coupling
Sieser, Janice E.,Singer, Robert A.,McKinley, Jason D.,Bourassa, Dennis E.,Teixeira, John J.,Long, James
, p. 1328 - 1335 (2012/01/12)
The process development is reported of a pivotal C-N bond formation involving ((7R,9aS)-octahydro-1H-pyrido[1,2-a]pyrazin-7-yl)methanol (2) undergoing nucleophilic aromatic substitution with 3-chlorobenzo[d]isoxazole (3) to furnish ((7R,9aS)-2-(benzo[d]isoxazol-3-yl)octahydro-1H-pyrido[1,2-a] pyrazin-7-yl)methanol (4) as a key intermediate for a family of compounds (1). Essential to the success of the coupling is the use of fluoride in combination with a phase transfer catalyst. The development of an alternative route to bicyclic piperazine 2 that uses l-aspartic acid (20) as a starting material to avoid the need for a classical salt resolution is described.
Synthesis, SAR and pharmacology of CP-293,019: A potent, selective dopamine D4 receptor antagonist
Sanner, Mark A.,Chappie, Thomas A.,Dunaiskis, Audrey R.,Fliri, Anton F.,Desai, Kishor A.,Zorn, Stevin H.,Jackson, Elisa R.,Johnson, Celeste G.,Morrone, Jean M.,Seymour, Patricia A.,Majchrzak, Mark J.,Faraci, W. Stephen,Collins, Judith L.,Duignan, David B.,Di Prete, Cecilia C.,Lee, Jae S.,Trozzi, Angela
, p. 725 - 730 (2007/10/03)
A series of novel, potent and selective pyrido[1,2-a]pyrazine dopamine D4 receptor antagonists are reported including CP-293,019 (D4 K(i) = 3.4 nM, D2 K(i) > 3,310 nM), which also inhibits apomorphine-induced hyperlocomotion in rats after oral dosing.
